ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,220.90
0.24%
S&P ASX All Technology
3,825.10
-0.11%
Brent Oil
73.285
0.00%
US Dollar vs AUD
1.6036
0.06%
Bitcoin
97,936.82
-0.75%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Carisma Therapeutics Inc (CARM) Share Price

Carisma Therapeutics Inc

Carisma Therapeutics Inc (CARM)

Carmanah Minerals Corp
Carrefour Property Development
0.399
0.011
(2.84%)
Closed 25 December 8:00AM
Delayed by 15 minutes
0.399
0.00
(0.00%)
After Hours: 8:00AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
0.399
Bid
0.3989
Offer
0.399
Volume
439,958
0.38 Day's Range 0.4075
0.3809 52 Week Range 3.16
Market Cap
16.658M
Previous Close
0.388
Open
0.38
Last Trade
4460
@
0.3989
(formt)
Last Trade Time
Financial Volume
US$ 171,321
VWAP
0.389403
Average Volume (3m)
220,862
Shares Outstanding
41,750,109
Dividend Yield
-
PE Ratio
-0.19
Earnings Per Share (EPS)
-2.08
Revenue
14.92M
Net Profit
-86.88M

About Carisma Therapeutics Inc

Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company's macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell t... Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company's macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company's lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Company's second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.carismatx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Carisma Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CARM. The last closing price for Carisma Therapeutics was US$0.39. Over the last year, Carisma Therapeutics shares have traded in a share price range of US$ 0.3809 to US$ 3.16.

Carisma Therapeutics currently has 41,750,109 shares in issue. The market capitalisation of Carisma Therapeutics is US$16.20 million. Carisma Therapeutics has a price to earnings ratio (PE ratio) of -0.19.

Ask ADVFN Intelligence (AI)

CARM Latest News

More News

Form 8-K - Current report

10 December 2024
Edgar (US Regulatory)

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline PR Newswire PHILADELPHIA, Dec. 9, 2024 Resources realigned to focus primarily on in vivo macrophage engineering...

10 December 2024
PR Newswire (US)

CARMILA : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers

Regulatory News: CARMILA (Paris:CARM) : Date Nombre d’actions composant le capital social Nombre réel de droits de vote (déduction faite des actions auto- détenues) Nombre théorique de droits de...

06 December 2024
Business Wire

Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference PR Newswire PHILADELPHIA, Nov. 27, 2024 PHILADELPHIA, Nov. 27, 2024 /PRNewswire/ -- Carisma Therapeutics...

27 November 2024
PR Newswire (US)

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024 PR Newswire PHILADELPHIA, Nov. 17, 2024...

17 November 2024
PR Newswire (US)

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma PR Newswire PHILADELPHIA, Nov. 8, 2024 New findings showcase the potential of in vivo...

08 November 2024
PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 November 2024
Edgar (US Regulatory)

Form 8-K - Current report

07 November 2024
Edgar (US Regulatory)

Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights PR Newswire PHILADELPHIA, Nov. 7, 2024 Initial results from the Phase 1 study of CT-0525, lead...

07 November 2024
PR Newswire (US)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.039-8.904109589040.4380.49630.38093569290.43885241CS
4-0.451-53.05882352940.850.8880940.38093735730.55253623CS
12-0.5686-58.76395204630.96761.130.38092208620.74426678CS
26-0.621-60.88235294121.021.70.38093006871.06368255CS
52-2.651-86.91803278693.053.160.38092338141.37536195CS
156-5.391-93.10880829025.799.76620.38092376363.17856376CS
260-5.391-93.10880829025.799.76620.38092376363.17856376CS

CARM - Frequently Asked Questions (FAQ)

What is the current Carisma Therapeutics share price?
The current share price of Carisma Therapeutics is US$ 0.399
How many Carisma Therapeutics shares are in issue?
Carisma Therapeutics has 41,750,109 shares in issue
What is the market cap of Carisma Therapeutics?
The market capitalisation of Carisma Therapeutics is USD 16.2M
What is the 1 year trading range for Carisma Therapeutics share price?
Carisma Therapeutics has traded in the range of US$ 0.3809 to US$ 3.16 during the past year
What is the PE ratio of Carisma Therapeutics?
The price to earnings ratio of Carisma Therapeutics is -0.19
What is the cash to sales ratio of Carisma Therapeutics?
The cash to sales ratio of Carisma Therapeutics is 1.12
What is the reporting currency for Carisma Therapeutics?
Carisma Therapeutics reports financial results in USD
What is the latest annual turnover for Carisma Therapeutics?
The latest annual turnover of Carisma Therapeutics is USD 14.92M
What is the latest annual profit for Carisma Therapeutics?
The latest annual profit of Carisma Therapeutics is USD -86.88M
What is the registered address of Carisma Therapeutics?
The registered address for Carisma Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Carisma Therapeutics website address?
The website address for Carisma Therapeutics is www.carismatx.com
Which industry sector does Carisma Therapeutics operate in?
Carisma Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BAOSBaosheng Media Group Holdings Ltd
US$ 7.10
(310.40%)
58.74M
HOURHour Loop Inc
US$ 4.40
(207.69%)
97.42M
GTIGraphjet Technology
US$ 0.61
(168.72%)
265.48M
CREVCarbon Revolution Public Ltd
US$ 9.16
(135.48%)
26.95M
AVGRAvinger Inc
US$ 1.45
(125.72%)
107.53M
SLGLSol Gel Technologies Ltd
US$ 0.9798
(-40.62%)
3.07M
DRCTDirect Digital Holdings Inc
US$ 3.71
(-32.55%)
23.82M
CHEKCheck Cap Ltd
US$ 1.55
(-31.11%)
3.49M
SYTASiyata Mobile Inc
US$ 0.5178
(-30.83%)
2.63M
BTFValkyrie ETF Trust II CoinShares Bitcoin and Ether Stratagy ETF
US$ 15.47
(-30.38%)
147.98k
SVMHSRIVARU Holding Ltd
US$ 0.0338
(20.71%)
280.27M
GTIGraphjet Technology
US$ 0.61
(168.72%)
265.48M
LITMSnow Lake Resources Ltd
US$ 0.5849
(52.84%)
181.22M
LCIDLucid Group Inc
US$ 3.20
(3.23%)
108.75M
RGTIRigetti Computing Inc
US$ 11.35
(3.56%)
108.38M

CARM Discussion

View Posts
PonkenPlonken PonkenPlonken 3 months ago
I appreciate you reaching out. I like to follow the money in bioland or predict where it might go. Hence i really like this. Their CAR M CD47 approach is not new and many wished for these trials. The risk however is huge hence no one bit this (monotherapy trial with safety as primary endpoint is almost random)

I am having a very close eye on this as they will share the first clinical data in q4. Any price increase prior might hint at things being right/a rally coming. The problem is, this is monotherapy only and not the one where they combine with the mRNA tech (which is likely where the good stuff is)

So down the road we will be getting some great hints here on whether this might be "THE next big thing" or not.... A LOT of targets nominated by them...
👍️0
jondoeuk jondoeuk 3 months ago
From this: “Without a doubt there's big biological risk here,” says Carisma CSO Michael Klichinsky. Researchers have yet to prove either the efficacy or the approvability of CAR macrophages. But solid tumours account for 90% of the cancer burden, making the possibility of activity in these settings with an in vivo reprogramming agent all the more appealing. “We’re going after a real unmet need,” he adds. https://www.nature.com/articles/d41573-024-00150-z
👍️0
Prestotic Prestotic 4 months ago
Vdog, your dog stock shedding another 8.33% today on a pathetic 2 million shares. Going to trips withou a contract soon. Hope you get this message. You could be in Carisma if only you listened.
👍️0
Prestotic Prestotic 4 months ago
Vdog has no Carisma Therapeutics. Losers like him love losers like VXIT. Carisma up 50 % in 2 weeks, Vxit down 50%. LOVE to say I TOLD YOU SO! How's your DD treating you JA
👍️0
Prestotic Prestotic 4 months ago
Eat shi* vdog
👍️0
Prestotic Prestotic 4 months ago
Another 50,000 getting accumulated/ covered @ $1.04. To the moon, soon.
👍️0
Prestotic Prestotic 4 months ago
No noise here because Carisma is not a penny stock. This has moved nicely off of the bottom of .80 from last week. Plus 20%. Positive results from phase 2 study will solidify deal with Moderna and get this back up to levels seen mid June. Today's action, including buy, buy, buy of 75000 shares at 3:30 pm shows accumulation, or at least some worried shorts covering. Looking for strong move up on phase 2 results.
👍️0
Prestotic Prestotic 4 months ago
No noise here because Carisma in not a penny stock. This has moved nicely off of the bottom of .80 from last week. Plus 20%. Positive results from phase 2 study will solidify deal with Moderna and get this back up to levels seen mid July. Today's action, including buy, buy, buy of 75000 shares around 2pm shows accumulation, or at least something worried shorts covering. Looking for strong move up on phase 2 results.
👍️0
CancunCharlie CancunCharlie 5 months ago
Is there anyone here?? No comments in over a month. I think this looks good, but I'm wondering why it's so quite here.
👍️0
PonkenPlonken PonkenPlonken 6 months ago
pretty strong
nice tech$
👍️0
glenn1919 glenn1919 6 months ago
CARM.......................https://stockcharts.com/h-sc/ui?s=CARM&p=W&b=5&g=0&id=p86431144783
👍️0
Awl416 Awl416 6 months ago
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
👍️0
Termite7 Termite7 7 months ago
Could it be CARM under $0.30 ....???.......Thanks!!!
👍️0
axelvento axelvento 7 months ago
$1.46 bouncer
👍️0
PonkenPlonken PonkenPlonken 8 months ago
https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-023-00537-x
MRNA provides the tech, 3bln + in biobucks and has not so distant private relative with TOP tier c suite.
👍️0
Monksdream Monksdream 9 months ago
CARM under $3
👍️0
mrplmer mrplmer 1 year ago
Whatever happened with their acquisition of Sesn Bio and their Bladder Cancer
👍️0
mrplmer mrplmer 1 year ago
Whatever happened with their acquisition of Sesn Bio and their Bladder Cancer
👍️0
81vette 81vette 1 year ago
1st higher high today and bid growing now,I got some 2.64,will see if dump continues or not
👍️0
81vette 81vette 1 year ago
Yea,distribution only so far today,I am watching for accumulation to start after this dumpathon,short interest went up 300% today also, 100k now,no sign of institutional buying yet,they currently hold 19%
👍️0
stock1ace1 stock1ace1 1 year ago
Red on news .. we no what that means lol
👍️0
81vette 81vette 1 year ago
Deal with Moderna for cancer cures,institutional might buy now lol,went up last time on this news,analysts target $9.50,short 2.45M,not optionable is good,gap filled down now,52 week low 2 weeks ago
👍️0

Your Recent History

NASDAQ
CARM
Carisma Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads